Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Warrants for shorts

<< Previous

Bullboard Posts

Next >>

Comment by Yajneon Dec 03, 2021 11:04pm

242 Views

Post# 34197649

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Warrants for shorts

Great post SB, I fully agree. To add, if an early offer does emerge, I think TLT has already set the stage, with it's latest data, for a bidding war. There are several BF players that will be impacted more that others if/when TLT receives BTD abd ultimately gets AA from the FDA. I should have read your post first before responding the link jaro posted. Yes, TLD1433 will hopefully have 'added weight' with FDA for future indications.

StevenBirch wrote: Let's face it TLT will not be bought out while being a $0.36 stock. There will be some intermediate price it gets to before any offer is made and that's why I think we will see some bump before the next report. There are catalysts for that bump and with any further approval from the FDA a second and/or third Phase 1b trial will be announced. It is then that I think we are on the clock because with the success of NMIBC, efficacy and safety, the early results from those trials will have added weight - if not from the FDA who have more rigid responsibility then the big pharma suitors who will want to be first in line and therefore create a bidding war. I have seen stocks that trade above the takeout price just on the speculation of competing offers that may never come!

That might be fantasy but it's my opinion and one thing I would like to dispel is this thought about a lowball buyout. Most people talk about buyouts based on their own personal needs or wants and based on their average cost or the size of their position and then do the math from there but in reality they are based on value or at least perceived value.

I think it's the perceived value that ensures we don't even get a lowball offer never mind accept one. I wouldn't want to be the one trying to put a value on this if my above scenario plays out and they start to get good early data from further indications. Then there is the covid wildcard.

This is probably the best two weeks we've had in two years because of the move and the volume to back it up. I like talk of buyouts and while I think still premature, not by years and possibly months, nobody is getting this company on the cheap.